11/02/2019 13:03:00

Lumere Closes Strategic Growth Capital Funding

CHICAGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Lumere, Inc., a leading provider of evidence-based analytics and services to reduce unwarranted and costly clinical variation, announced today the closure of a significant round of funding led by Heritage Group. The additional capital will be used to develop and further expand service offerings that enable evidence-led change at health systems nationwide.

“Today, health systems in more than 40 states rely on our proprietary data to make evidence-based decisions when evaluating and optimizing drug and device utilization. Our new services make it possible for physicians to leverage these insights when planning for their cases,” said Hani Elias, JD, MPH, Lumere co-founder and CEO.

“We invest in companies that are passionate about unraveling the complexities of U.S. healthcare and have demonstrated positive momentum. We have been exceedingly impressed with Lumere’s growth during the past three years and are eager to continue supporting their mission,” said Jesse Bland, Principal, Heritage Group, a growth equity firm backed by some of the nation’s leading healthcare companies. Heritage Group also led Lumere’s Series B financing in June 2016.

Combining the power of clinical evidence, data and subject matter expertise, Lumere has helped more than 650 healthcare facilities reduce unnecessary costs and clinical variation since 2012. Lumere’s service offerings have been developed as a result of customer need to bring evidence and analytics closer to the individual physician and have helped health systems save millions of dollars in supply and drug spend while improving overall patient outcomes.

“Healthcare organizations are under significant pressure to eliminate both unnecessary variation and cost,” said Scott Lancaster, MD, MBA, Clinical Director, Spectrum Health Ventures, a participating investor. “We leverage Lumere’s research and evidence insights to ensure we are using products with the strongest clinical evidence and best outcomes for our patients, all while lowering costs. We are committed to supporting Lumere in its quest to equip physicians with tools and insights to make the best decisions possible on every case they perform.”

About Lumere

Lumere is at the forefront of clinical decision making for drugs and devices, offering evidence-based solutions and services for all providers that improve care and reduce cost across the patient journey. For more information, visit lumere.com, find us on LinkedIn, follow @LumereHQ on Twitter and like us on Facebook.

For media inquiries, please contact:

Giana Gaughan

PR Manager, Lumere

ggaughan@lumere.com

lumerelogo.JPG

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Apr
I:SP500
  Hejsa.   Lige lidt læsestof til påsken.   Langsigtet konjunktur:   Overraskende stigning i de le..
47
18 Apr
 
Jeg har modtaget flg. fra Delfin : "Nå, så er jeg blokeret på EI. Hvorfor ved jeg ikke. Jeg har ikke..
36
17 Apr
VELO
  Den eneste TA-ekspert var for mig alpehue, og nogle ganske få andre. Langt de fleste, som udtaler ..
28
15 Apr
VELO
Solen skinner++Envarsus viser vejen med endnu engang rigtig gode data. https://www.ncbi.nlm.nih.gov..
24
17 Apr
 
EI hvorfor har I slettet mit indlæg 414414 og hele debatten om hvad en moderater bør blande sig i ? ..
21
17 Apr
TEVA
Den er også svær lige nu fordi mange korte og lange signaler krydser ind over hinanden lige nu. Men ..
11
15 Apr
VWS
Vestas i 600.. 😊 Det er en stor dag... Tillykke til de tålmodige og trofaste aktionærer.. Endelig ..
11
20 Apr
NOVO-B
En lille påskehilsen fra Alpe, med mulighed for Novo.   https://invst.ly/al3nf  
10
18 Apr
 
Hej CasHolm   da du har en alder af 12 år syntes jeg at det er vigtigt at du gøre op med dig selv om..
10
17 Apr
 
Hej 'outlook', dit opslag blev slettet fordi det ikke omhandlede markedet eller værdipapirer på noge..
10

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Sprint Corp. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 April 2019 12:04:22
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB4 - 2019-04-21 13:04:22 - 2019-04-21 12:04:22 - 1000 - Website: OKAY